Optimizing Chemotherapy Scheduling By Iteratively Solving a Recurrence Equation

Authors

  • Hui Jiang Institute for Computational and Mathematical Engineering, Stanford University, USA.
  • Yifan Liu Department of Systems Engineering and Operations Research, George Mason University, USA
  • Zheng Su Genentech Inc, USA

Abstract

We illustrate how an iterative method and the idea of recurrence can be employed to optimize chemotherapy scheduling. We take the density of host and cancer cells as the states, and aim at minimizing the treatment period for each state. We derive the equation satisfied by the optimal values of the objective function at different states. The theorem of existence and uniqueness for the solution to this equation is proved, and some important properties of the optimal values of the objective function are presented. The optimal treatment schedule can be derived directly from the optimal objective function values at different states. We use an iterative method to solve the equation numerically. Some ideas to further enhance the model are discussed.

Downloads

How to Cite

Jiang, H., Liu, Y., & Su, Z. (2008). Optimizing Chemotherapy Scheduling By Iteratively Solving a Recurrence Equation. Algorithmic Operations Research, 3(2). Retrieved from https://journals.lib.unb.ca/index.php/AOR/article/view/9703

Issue

Vol. 3 No. 2 (2008)

Section

Articles

License

The copyright of the submitted article is hereby transferred to “Preeminent Academic Facets Inc. (the “publisher”) to the extent possible by the laws in the respective countries of the author(s). The author(s) retain all other rights including the following: 1. Any patents and trademark rights. 2. Right to post a pre-print version of the paper on the author’s personal website which is not used for commercial purposes. The author(s) warrant that the work is original, it has not been published elsewhere, it is not currently under consideration for publication in any form, and it does not infringe any copyright laws. The signing author or agent further warrants that all authors, if applicable, have been informed of the terms of this agreement and obtained the approval and authority to sign the agreement.